A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease "ARRIVE"


Phase 3 Results

Summary of Purpose

The use of acetylsalicylic acid in the primary prevention of cardiovascular events has been extensively studied but to a lesser extent in patients with moderate levels of cardiovascular risk. The current study is designed to prove the efficacy and tolerability of 100 mg enteric-coated Aspirin versus placebo in the prevention of cardiovascular disease (CVD) events, which include fatal and nonfatal myocardial...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 4 January 2018.

5 Jul 2007 12 Jul 2007 15 Nov 2016 15 Nov 2016 1 Jan 2018 15 Nov 2017
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
  • Purpose: Prevention
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment


  • Bayer Clinical Trials Contact Tony Johns tony.johns.b@bayer.com Phone: 973-254-4675 2nd email contact: james.angello.b@bayer.com